Dupilumab Achieves Early Disease Control in Bullous Pemphigoid: A Case Series with TARC-based Biomarker Evaluation
DOI:
https://doi.org/10.2340/actadv.v105.43999Keywords:
bullous pemphigoid, dupilumab, biologic therapy, IL-4, IL-13, disease activity biomarkers, thymus and activation-regulated chemokineDownloads
References
Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res 2018; 66: 6–17. DOI: https://doi.org/10.1007/s12026-017-8975-2
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348. DOI: https://doi.org/10.1056/NEJMoa1610020
Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 2022; 13: 928621. DOI: https://doi.org/10.3389/fimmu.2022.928621
Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol 2023; 159: 953–960. DOI: https://doi.org/10.1001/jamadermatol.2023.2428
Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study. Int Immunopharmacol 2023; 125: 111157. DOI: https://doi.org/10.1016/j.intimp.2023.111157
Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107: 535–541. DOI: https://doi.org/10.1067/mai.2001.113237
Kakinuma T, Wakugawa M, Nakamura K, Hino H, Matsushima K, Tamaki K. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br J Dermatol 2003; 148: 203–210. DOI: https://doi.org/10.1046/j.1365-2133.2003.05066.x
Suzuki M, Yamaguchi Y, Nakamura K, Kanaoka M, Matsukura S, Takahashi K, et al. Serum thymus and activation-regulated chemokine (TARC/CCL17) may be useful to predict the disease activity in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2021; 35: e121–e124. DOI: https://doi.org/10.1111/jdv.16851
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Saori Takamura, Tomoo Fukuda
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
